National practice trends for the surgical management of lung cancer in the CMS population: an atlas of care

Joseph D. Phillips1,2#, Ian C. Bostock1, Rian M. Hasson1,2, Philip P. Goodney1,2, David C. Goodman1,2, Timothy M. Millington1,2, David J. Finley1,2

1Dartmouth Hitchcock Medical Center, Lebanon, NH, USA; 2Geisel School of Medicine at Dartmouth, Lebanon, NH, USA

Contributions: (I) Conception and design: JD Philips, IC Bostock, DJ Finley; (II) Administrative support: JD Phillips, DJ Finley; (III) Provision of study materials or patients: JD Phillips, DJ Finley; (IV) Collection and assembly of data: JD Philips, IC Bostock, DJ Finley; (V) Data analysis and interpretation: All authors; (VI) Manuscript writing: All authors; (VII) Final approval of manuscript: All authors.

#These authors shared first authorship.

Correspondence to: Joseph D. Phillips, MD. Thoracic Surgery, One Medical Center Drive, Lebanon, NH 03756, USA. Email: joseph.d.phillips@hitchcock.org.

Background: Video-assisted thoracoscopic surgery (VATS) has been established as a safe and effective alternative to an open approach for the treatment of early-stage lung cancer. Despite this, differences in utilization across the nation are present. The aims of this study were to: (I) characterize trends in the use of open surgery and VATS for the management of lung cancer across the United States, and (II) describe if particular regions of the country utilize minimally invasive surgery more frequently.

Methods: We studied all Medicare beneficiaries from the ages of 65 to 99 years with full Part A and B coverage and no HMO coverage for the years of 2006 and 2014 (the most recent year available at the time of this analysis). Beneficiaries with a diagnosis of lung cancer (ICD-9 codes: 162.0 162.2 162.3 162.4 162.5 162.8 162.9) were selected. Rates of thoracoscopic surgery (CPT codes: 32663, 32666, 32667, 32668, 32669, 32670, 32671) and open lung resections (32505, 32506, 32507, 32608, 32440, 32442, 32445, 32480, 32482, 32484, 32486, 32488) were calculated by year and region. Rates in 2006 and 2014 with descriptive statistics and a univariate analysis were performed using Student’s t-test and chi-square, as appropriate. A two-sided P value <0.05 was considered statistically significant.

Results: A total of 24,368,333 and 23,921,059 beneficiaries for the years of 2006 and 2014 were analyzed. A diagnosis of lung cancer was detected in claims of 167,418 patients (0.7%) in 2006 and 167,506 patients in 2014 (0.7%), which was not significantly different (P=0.7). Among these lung cancer patients, a surgical intervention was performed in 17,249 patients (10.3%) during 2006 and 18,603 patients (11.1%) in 2014 (P=0.01). Among those undergoing surgery, a VATS approach was performed in 2,512 patients (15%) during 2006 and 9,578 patients (54%) during 2014 (P=0.001). In 2006, California, New York, and New Jersey performed the most VATS procedures, in comparison to 2014, when New York, Florida, and California performed the highest number of VATS procedures.

Conclusions: While the prevalence of lung cancer in the United States was unchanged between 2006 and 2014, the use of VATS techniques increased five-fold. Further studies to better understand the adoption or availability of new surgical techniques in lung cancer populations across geographic regions and patient populations are necessary.

Keywords: Lung cancer; thoracoscopy; practice trends; minimally invasive techniques

Submitted Nov 08, 2018. Accepted for publication Dec 31, 2018. doi: 10.21037/jtd.2019.01.05

View this article at: http://dx.doi.org/10.21037/jtd.2019.01.05
Introduction

Nearly 600,000 deaths occur each year in the United States from cancer, with lung cancer being the most common cause (1). Although advanced stage lung cancer still represents the majority of newly diagnosed cases, surgery is the standard of care for early-stage non-small cell lung cancer (NSCLC), defined as clinical T1-2N0 disease. In medically operable patients, this offers the greatest chance of long-term survival (2). Although traditional surgery involves the use of an open approach, over the last two decades there has been a rising interest in minimally invasive video-assisted thoracoscopic surgery (VATS). The specific use of VATS for lobectomy has been established as a safe and effective alternative to open surgery for the management of early stage lung cancer. Several studies have associated VATS with a lower operative morbidity, transfusion requirement, chest tube duration, shorter hospital stays, and improved survival compared to open surgery (3-8). Additionally, similar long-term oncologic results between an open technique and VATS have been demonstrated (9-15).

Given that VATS can lead to improved short-term and similar long-term outcomes, the adoption of these techniques across the country has the potential to drastically impact the costs of healthcare. However, the national adoption of VATS is unknown, and generalized implementation has been challenged by debate of the regionalization of thoracic surgery to high-volume centers and the resultant financial and ethical implications related to this practice (16-18).

Currently, there is a paucity of population data regarding the surgical practice trends for the management of lung cancer in the United States, particularly in those age 65 or older. This gap represents a challenge for generating national policy, practice recommendations/guidelines, and training certifications/credentialing. Consequently, the aims of this study were to: (I) characterize open versus VATS surgical practice trends for the management of lung cancer in the United States, and (II) describe if particular regions of the country utilize minimally invasive surgery more frequently.

Methods

The Dartmouth Atlas

The Dartmouth Atlas is a statistical instrument that uses Medicare claims data to analyze and compare variables in the health care system across regions of the United States. These datasets originate from The Centers of Medicare and Medicaid (CMS) and are processed twice per year within national, regional, and local markets. A significant limitation of the Dartmouth Atlas is that the data provided is in an aggregated form for specific conditions and designated time periods (19).

The Denominator file contains 100% population beneficiary demographic and enrollment information, which is available from years 2001 to 2009. The Master Beneficiary Summary File (MBSF) is available from years 2009 forward (through 2014 at the time of this study). These two data sources are utilized during the rate generator request to establish the population of interest (19).

Data source

An exclusive national sample from the physician and supplier and denominator files from the Centers for Medicare and Medicaid Services in the years of 2006 and 2014 was utilized to identify all lung cancer diagnoses made in Medicare beneficiaries during those two years. The physician and supplier file contains all claims submitted by physicians for performance of procedures under the Medicare Part B program, including Current Procedural Terminology (CPT) codes, International Classification of Diseases, Ninth Revision (ICD-9) diagnosis codes, date of procedure, and age, sex, and race/ethnicity of the beneficiary undergoing the procedure (20-22). The denominator file contains information about eligibility by year for the Medicare Part B program and information about age, sex, and race/ethnicity of eligible beneficiaries. Our exclusion criteria included age younger than 65 years or older than 99 years and unknown race/ethnicity. This analysis was performed through an Institutional Review Board approval of the Dartmouth Atlas of Healthcare.

Hospital utilization

Inpatient hospital utilization is measured using the 100% MedPar file available for all years (currently 2001 to 2014). Each record represents a beneficiaries’ stay in an inpatient hospital and may represent more than one claim. This depends on the length of stay and the amount of services received. The MedPar file contains diagnosis codes (ICD-9 dx) and procedures codes (ICD-9 sx and DRGs) to identify the beneficiaries’ diagnosis and provided treatment (20-22).

Physician visits

Physician visits are measured using the Part B carrier file.
This is available at 20% in 2002, 40% from years 2003 through 2005, and 100% thereafter (through 2014). Because it was the first year of complete data, we chose 2006 as our initial time point. Each of these records represents an individual contact from a beneficiary and a medical or associate provider. In addition, claims for labs, ambulance services, and ambulatory service centers are included in this file. For each date of service, the Part B Carrier file records include ICD-9 diagnosis codes and current CPT codes to identify the beneficiaries’ diagnosed condition and type of treatment provided (20-22).

Study population

Lung cancer diagnosed beneficiaries were identified from claim ICD-9 codes: (trachea 162.0, main bronchus 162.2, upper lobe 162.3, middle lobe 162.4, lower lobe 162.5, other parts of bronchus 162.8, and unspecified 162.9). This group of patients represented all lung cancer diagnoses in Medicare beneficiaries during each study year. Patients were then divided into those with no lung resection, those with a VATS surgical thoracoscopy with single lobectomy 32663, surgical thoracoscopy with therapeutic wedge resection 32666, surgical thoracoscopy with therapeutic additional wedge resection 32667, surgical thoracoscopy with diagnostic wedge resection followed by anatomical lung resection 32668, thoracoscopy segmentectomy 32669, thoracoscopy bilobectomy 32670, thoracoscopy pneumonectomy 32671, and those undergoing open resection (OR), as defined by thoracotomy with therapeutic wedge resection 32505, thoracotomy with additional therapeutic wedge resection 32506, thoracotomy with diagnostic wedge resection followed by anatomic lung resection 32507, thoracotomy with diagnostic biopsies of lung nodule/mass 32608, removal of lung 32440, removal of lung with segment of trachea 32442, removal of lung extrapleural 32445, single lobectomy 32480, bilobectomy 32482, removal of lung segmentectomy 32484, removal of lung with circumferential resection of segment of bronchus 32486, and removal of lung with all remaining lung follow previous removal of a portion of lung 32488. We did not include the modifier for robotic surgery (S2900), as this code was only established in July of 2005 and represents an additional procedural code to the main procedure.

Study endpoints

The primary endpoint of the analysis was the rate of VATS versus OR among patients undergoing surgical management of lung cancer during the study period. The secondary endpoint was to determine the geographic variation in use of VATS versus OR.

Statistical analysis

Rates for each of the procedures were calculated in the years of 2006 and 2014. The numerator for calculating the crude rate consisted of the number of VATS or OR procedures in each year selected; the denominator consisted of the number of beneficiaries in the 100% Medicare Part B program sample eligible. The indirect method of standardization was used to adjust for changes in age, sex, and race/ethnicity. All rates in the analysis were expressed as the number of claims per 1,000 Medicare beneficiaries and then converted to percentages.

In order to examine variation across the US in types of procedure performed, we calculated the rates of VATS and OR within each Hospital Referral Region (HRR). HRRs are defined as specific regions that represent healthcare markets with associated tertiary medical care and surgical procedures that have been validated to study geographic variation in healthcare delivery (23-28). There are currently 306 HRRs in the US with each HRR containing a minimum population size of 120,000 and at least one hospital that performs major cardiothoracic procedures. After defining crude rates of VATS and OR within each HRR for each of the years in our analysis, we indirectly adjusted each rate for differences in age, sex, and race across regions as described previously (23,28). A Student’s t-test was utilized to compare rates between regions and years. Significance across years was evaluated using nonparametric tests. Probability values <0.05 were considered significant. In addition, we created heat maps that were normalized using the concentration of events per HRR by State. All analysis was performed using SAS (SAS Institute, Cary, NC, USA), and STATA 10 (College Station, TX, USA).

Results

Incidence of lung cancer and trends of surgical management

In 2006, a total of 24,368,333 Medicare beneficiaries were screened and a diagnosis of lung cancer was present in 167,418 patients (0.7%). In 2014, a total of 23,921,059 Medicare beneficiaries were screened and a diagnosis of lung cancer was present in 167,506 patients (0.7%). There
was no statistical difference in the incidence of lung cancer between the years 2006 and 2014 in Medicare beneficiaries with a diagnosis of lung cancer (P=0.7) (Figure 1). Overall, the rates of lung cancer did not change appreciably during this time by state. For example, rates of lung cancer prevalence were 6.2 per 100,000 in California in 2006 and 5.6 per 100,000 in 2014 (P=0.6). Figure 2 demonstrates a set of heat maps from the years 2006 and 2014, depicting the geographic variation in the rate of a lung cancer diagnosis by state across the United States.

In 2006, 17,249 (10.3%) patients underwent surgery as a treatment for lung cancer, compared to 18,603 (11.1%) in 2014 (P=0.01). A VATS approach was performed in 2,512 patients (15%) during 2006 and 9,578 patients (54%) during 2014. Nationally, the rate of VATS increased during this time period by 39% (Figure 1). The rate difference over time was noted to be statistically significant (P=0.001). Figure 3 depicts the rate of VATS by state in a set of maps for the years of 2006 and 2014.

**Trends in surgical management by geographic region**

In 2006, California, New York, and New Jersey performed the highest total number of VATS procedures. By 2014, New York, Florida, and California performed the highest total number of VATS procedures. Table 1 lists the ten states with the most VATS interventions, both in 2006 and 2014. Overall, there was a 2-fold variation between states with Florida, New York and California having the highest total number of VATS procedures in 2014. The lowest utilization of VATS was in Colorado, Iowa, and Arkansas in 2006 compared with Utah, Alaska, and South Dakota in 2014. Interestingly, the highest percentage of VATS interventions in 2006 across the US was in New Jersey (28%), Maryland (26%), and New York (26%). In 2014, the highest percentages of VATS in states performing at least 100 surgical resections per year were in New York (70%), Massachusetts (70%), and Virginia (63%).

**Discussion**

VATS lobectomy has been associated with excellent clinical outcomes having a 30-day mortality rate of 1.9%, and a total 90-day mortality rate of 2.5% (29). In addition, a recently published study evaluating the long-term survival (5 years) of clinical stage I NSCLC based on surgical approach found similar results between minimally invasive options and thoracotomy, and the specific use of VATS was associated with a shorter length of stay (30). Furthermore, in a recent review of cost analyses, Menna et al. concluded that significant cost savings reported with VATS compared to thoracotomy for lung cancer surgery were likely related to hospital savings associated with better outcomes, particularly when an experienced surgeon performs the surgery (31).

Despite the above benefits of VATS in lung cancer surgery, our data suggest that there is clear variation in the dissemination of these techniques across the United States. Though patients were five times more likely to receive VATS procedures in 2014 as compared to 2006, significant regional variation exists in the degree to which these techniques are utilized. Some regions of the country have aggressively adopted minimally invasive surgery, while others are using it less commonly. We found the highest number of VATS cases in New York, Florida, and California in 2014. The three states with the highest percentage of VATS utilization in 2014 were New York, Massachusetts and Virginia.
Figure 2 Geographic variation in the years of 2006 and 2014, depicting the rate of lung cancer diagnosis by state.

Substantial geographic variation in the surgical management of NSCLC is not unique to the United States. After reviewing the use of curative surgical resection and 1-yr mortality in patients with NSCLC in England, significant geographic variation in technique was also demonstrated, even after adjustment for age, gender, and
socioeconomic status (32). The authors hypothesized that these variations are the result of disparities in referral wait times, stage at diagnosis, access to non-surgical treatments, and level of involvement of thoracic surgeons. In the United States, geographic variation in the use of adjuvant therapies following resected NSCLC has also been identified (33).

While there is an overall paucity of contemporary data evaluating the geographic utilization of surgery overall for NSCLC across the United States, we observed that in the CMS population, between HRRs, there was more than a 2-fold difference in the use of VATS. This suggests that there are geographical, or possible population-based,
influences in the adoption of this technology and this has the potential for significant impact on surgical training and treatment availability in these regions.

To address these variations, some have advocated for the use of VATS as the standard of care for operable lung cancer with routine referral to high-volume centers and multidisciplinary treatment teams, particularly for locally advanced disease. The regionalization of thoracic surgery is a complex topic, with recent reviews questioning the actual association between volume and quality (34). In addition, surgical databases measuring quality often do not reflect patient and family satisfaction, quality of life after procedures, and the potential financial and emotional difficulties that travelling significant distances to a regional center may cause. Our data demonstrate that significant variations in the utilization of VATS techniques exist across geographic regions in the United States in the treatment of NSCLC. Now that these differences have been identified, further studies are required to help clarify the underlying issues related to the adoption of VATS in areas with low utilization.

**Study limitations**

Our analysis has several limitations related to the use of an administrative database. First, patients in this analysis...
are Medicare recipients, and thus the results must be understood in the context of patients being ≥65 years of age. Second, patients were identified in our analysis based on Part B CPT codes for thoracoscopic procedures or thoracotomy, and miscoding of procedures may have occurred. It is not possible to determine whether the use of thoracoscopy increased secondary to a higher number of diagnostic resections rather than therapeutic resections, although the intent of the surgical procedure may be inferred based on the CPT codes. Lastly, this analysis does not contain demographic information on the study population or data on in-hospital morbidity or long-term survival, as it is aggregated HRR level data. There is no available information regarding cancer stage or the type of surgeon performing the procedures. Despite these limitations, we feel the study adds meaningful data on the contemporary adoption of VATS in the treatment of NSCLC across the United States, and demonstrates the variation in types of surgical interventions delivered between different regions of the country.

Conclusions

While the prevalence of lung cancer in the United States was unchanged from 2006 to 2014 in the CMS population, surgical management of NSCLC has increased over time, in this population. A change in surgical practice patterns was evident, with a significant increase in the use of VATS techniques in more than 50% of cases after this eight-year period. There is need for future studies focused on investigating variables that affect the use or availability of VATS across regions of the country, and in the non-CMS population.

Acknowledgements

None.

Footnote

Conflict of Interest: Podium presentation: Academic Surgical Congress 2018, January 30th to February 1st in Jacksonville, FL.

Ethical Statement: This analysis was performed through an Institutional Review Board approval of the Dartmouth Atlas of Healthcare.

References


